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External beam radiation therapy (XRT) with concomi-
tant temozolomide and 6 cycles of adjuvant temozolo-
mide (5/28-day schedule) improves survival in patients
with newly diagnosed glioblastoma compared with
XRT alone. Studies suggest that dose-dense temozolo-
mide schedules and addition of cytostatic agents may
further improve efﬁcacy. This factorial design phase I/
II protocol tested dose-dense temozolomide alone and
combined with cytostatic agents. Patients with newly
diagnosed glioblastoma received fractionated XRT to
60 Gy concomitant with temozolomide (75 mg/m
2/
day for 42 days). In the phase I portion, patients with
stable disease or radiologic response 1 month after che-
moradiation were randomized to adjuvant temozolo-
mide alone (150 mg/m
2/day, 7/14-day schedule) or
with doublet combinations of thalidomide (400 mg/
day), isotretinoin (100 mg/m
2/day), and/or celecoxib
(400 mg twice daily), or all 3 agents. Toxicity was
assessed after 4 weeks. Among 54 patients enrolled
(median age, 52 years; median Karnofsky performance
status, 90), adjuvant treatment was not administered
to 12 (22%), primarily because of disease progression
(n 5 10). All combinations were well tolerated. Grade
3/4 lymphopenia developed in 63% of patients, but no
related infections occurred. One patient treated with
temozolomide plus isotretinoin plus thalidomide had
dose-limiting grade 3 fatigue and rash, and 1 patient
receiving all 4 agents had dose-limiting grade 4 neutro-
penia. Venous thrombosis occurred in 7 patients, 4 of
whom received thalidomide. From study entry, median
survival was 20 months and the 2-year survival rate
was 40%. Multiple cytostatic agents can be safely com-
bined with dose-dense temozolomide. The factorial-
based phase II portion of this study is currently ongoing.
Keywords: dose-dense, glioblastoma, glioma,
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L
ong-term survival of patients with malignant
gliomas remains poor. Population-based studies
estimate that the 3-year survival rate for patients
with glioblastoma is 5% or less.
1,2 Conventional treat-
ment for newly diagnosed glioblastoma has traditionally
consisted of initial surgical resection followed by fractio-
nated external beam radiation therapy (XRT) with or
without chemotherapy, usually with regimens contain-
ing alkylating agents. However, until recently, the
beneﬁt of chemotherapy in this setting remained contro-
versial. Temozolomide, an oral alkylating agent, has
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studies in patients with malignant gliomas,
3–5 primarily
in the recurrent setting. The large phase III trial con-
ducted by the European Organisation for the Research
and Treatment of Cancer (EORTC) and the National
Cancer Institute of Canada (NCIC) demonstrated a sig-
niﬁcant survival beneﬁt for patients with newly diag-
nosed glioblastoma who were treated with
temozolomide during XRT (ie, concurrent chemoradia-
tion) and as adjuvant therapy thereafter.
6 Statistically
signiﬁcant improvements were noted in progression-free
survival (PFS) (median 6.9 vs 5.0 months; P , .001),
overall survival (median 14.6 vs 12.1 months;
P , .001), and the 2-year survival rate (26% vs 10%)
compared with XRT alone. Moreover, chemoradiation
was well tolerated in that study with an excellent
safety proﬁle. On the basis of that landmark study
reported by Stupp et al.,
6 XRT with concurrent and
adjuvant temozolomide has become the standard of
care for patients with newly diagnosed glioblastoma.
In addition, a correlative study determined the methyl-
ation status of the O
6-methylguanine-DNA methyltrans-
ferase (MGMT) promoter region in tumor tissue from
patients enrolled in the EORTC/NCIC study.
HypermethylationoftheMGMTpromoterregionsilences
gene expression with a resultant decrease in MGMT
protein synthesis. The correlative study reported by Hegi
et al.
7 suggested that MGMT methylation in the tumor
was associated with improved survival compared with
an unmethylated MGMT promoter (18 vs 12 months,
respectively).Thisobservationhasgeneratedconsiderable
interest in developing strategies to modulate MGMT
activity and thereby improve response and survival. The
study by Tolcher et al.
8 demonstrated that dose-dense
temozolomide regimens can modulate MGMT activity
in the peripheral blood mononuclear cells of treated
patients. Tolcher et al. investigated 2 dosing regimens,
the 7/14-day schedule (7 consecutive days on treatment
followedby7daysofftreatment)andthe21/28-daysche-
dule(21consecutivedaysontreatmentfollowedby7days
off treatment), and showed that there was progressive
depletion of MGMT activity throughout the dosing
period.
8 Subsequently, Wick et al.
9 reported that the 7/
14-day temozolomide regimen yielded a 6-month PFS
rate of 48% in patients with recurrent glioblastoma who
had not had prior treatment with temozolomide.
Inadditiontoalteringthedosingscheduleoftemozolo-
mide, there has been interest in examining the utility of
combining temozolomide with various cytostatic agents
that have nonoverlappingtoxicityproﬁles. Severalcombi-
nationsoftemozolomideandcytostatic drugs such astha-
lidomide, isotretinoin, and marimastat have been
evaluated in patients with recurrent malignant gliomas,
and the preliminary results are promising. Reported
6-monthPFSrateswere24%fortemozolomideplusthali-
domide,
1035%fortemozolomideplusisotretinoin,
11 and
39% for temozolomide plus marimastat.
12 Preclinical
studies using malignant glioma cell lines have also shown
that celecoxib exerts both cytostatic and potentially cyto-
toxiceffectsinvitro,
13,14andastudyusingaC6ratglioma
orthotopic model suggested synergy between
temozolomide and celecoxib.
15 These studies support the
feasibilityandpossibleutilityofcombiningtemozolomide
with these agents in the treatment of malignant gliomas,
although deﬁnite conclusions about the most effective
combinationcannotbemadeintheabsenceofrandomized
trials.
Therefore, we designed a clinical trial to evaluate the
potential beneﬁt of combining a dose-dense adjuvant
temozolomideregimen(7/14-dayschedulefollowingche-
moradiation) with cytostatic agents including thalido-
mide, isotretinoin, and/or celecoxib. In order to
efﬁcientlytestallthepossiblecombinations,arandomized
factorialdesignprotocolwasdeveloped(Fig.1).Thisnovel
designrequires accrualofonly22patients perarm tostat-
isticallyevaluatethepotentialbeneﬁtofeachcombination
anddeterminewhetherthereisabeneﬁttotripletorquad-
ruplet combinations compared with doublet combi-
nations. Although the safety proﬁle of temozolomide in
combination with each of these agents individually has
been previously established, the safety of the triplet and
quadruplet combinations had to be determined in a
phase I study before the full phase II protocol could be
initiated. The ultimate goal of this study is to develop
new treatment regimens that build on the established efﬁ-
cacy of chemoradiation with XRT plus temozolomide for
patients with newly diagnosed glioblastoma.
Patients and Methods
Patients
Eligiblepatientswereatleast10yearsofageandmusthave
had histologically conﬁrmed supratentorial glioblastoma,
a Karnofsky performance status (KPS) greater than 60,
adequate bone marrow function (absolute neutrophil
c o u n to fm o r et h a n1 5 0 0 /mm
3 and platelet count
greater than or equal to 100000/mm
3), adequate liver
function (serum glutamic pyruvic transaminase and alka-
line phosphatase less than 2 times the upper limit of insti-
tutional normal [ULN] and bilirubin less than 1.5 times
ULN), and adequate renal function (blood urea nitrogen
Fig. 1. Phase II factorial study design. XRT, external beam radiation
therapy; TMZ, temozolomide; thal, thalidomide; CRA, isotretinoin.
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before enrollment. A baseline postoperative gadolinium-
enhanced magnetic resonance imaging (GD-DPTA MRI)
scan was performed within 21 days before enrollment.
Patientswithahistoryofanyothercancer(exceptnonme-
lanomaskincancerorcarcinomainsituofthecervix)were
noteligibleunlesstheywereincompleteremissionandoff
all therapy for that disease for a minimum of 3 years.
Patients with serious intercurrent medical illness were
excluded. Patients with allergy to sulfa drugs were
excluded due to the potential for cross-reactions to cele-
coxib.Pregnancywasnotpermitted,andpatientsofchild-
bearing potential were required to use adequate
contraception. All patients were required to provide
informed consent, indicating that they were aware of the
investigationalnatureofthisstudyinkeepingwiththepol-
icies of the MD Anderson Cancer Center Institutional
Review Board.
Study Design
ThisphaseI/IIfactorialdesignstudyhad8treatmentarms
(Fig. 1): arm 1 consisted of single-agent temozolomide;
arms 2, 3, and 4 combined temozolomide with 1 other
agent (either thalidomide, isotretinoin, or celecoxib);
arms 5, 6, and 7 combined temozolomide with 2 agents
(either thalidomide + isotretinoin, thalidomide + cele-
coxib, or isotretinoin + celecoxib); and once the
maximum-tolerated doses were determined for these 3
tripletregimens,thequadruplet regimenoftemozolomide
plusthalidomide, isotretinoin, andcelecoxibwastestedin
arm 8. Patients with evidence of tumor progression 4
weeks after completing chemoradiation were removed
from the study before randomization, and new patients
wereaccruedtoreplacethemtoevaluatetreatment-related
toxicity.However,thesepatientswereincludedintheefﬁ-
cacyanalysis.InthephaseIportionofthestudy,treatment
with single-agent temozolomide (arm 1) was included to
obtain further information on the safety proﬁle of this
dose-dense regimen, and no patients were enrolled in
arms 2, 3, or 4 because the safety proﬁle of these combi-
nations has been previously established.
The primary endpoint was safety and tolerability.
Secondary endpoints were overall median survival and
2-year survival rate.
Treatments
After maximal surgical resection, patients were treated
with XRT administered over a period of 6 weeks to a
total dose of 60 Gy (2-Gy fractions), and temozolomide
(75 mg/m
2/day) was administered daily (7 days per
week) for the entire 6 weeks of XRT. Four weeks after
completing concurrent chemoradiation, a GD-DPTA
MRI scan of the brain was performed, and if there was
noevidenceoftumorprogression,patientswererandom-
ized to adjuvant chemotherapy. All patients received
adjuvant temozolomide at a dose of 150 mg/m
2/day on
the 7/14-day schedule. Patients were treated for a
maximumof12cycles;eachcyclewasdeﬁnedas28days.
The starting dose of each agent was determined based
on previously published studies.
16–18 The dosing sche-
dules started at the target dose and no dose escalation
was performed since the objective was to determine the
safety and tolerability of the different combinations.
A minimum of 3 patients were enrolled into each treat-
ment arm and if the starting dose was not associated
with serious dose-limiting toxicity, that dose was used
for the phase II portion of the study and the phase I arm
was closed. In the event of any serious dose-limiting tox-
icity, dose adjustments were allowed for all agents, and
additional patients were enrolled in that arm. If 1 of 3
patients developed a serious dose-limiting toxicity, an
additional 3 patients were enrolled. If 2 or 3 patients
developed a dose-limiting toxicity, an additional 3
patients would be enrolled at the next lower dose level.
The phase II dose was deﬁned as the dose level
where less than 33% of the patients developed a
treatment-related dose-limiting toxicity. Information on
the starting dose of each agent and protocol-deﬁned
dose adjustments are provided in Table 1.
Assessments
Complete blood count with differential, total protein,
albumin, calcium, phosphorus, glucose, blood urea
Table 1. Starting dose and dose adjustments
Treatment arm Agent Schedule Starting dose/day Dose level
21 22 23
1 Temozolomide Days 1–7, 15–21 *150 mg/m
2 125 100 100
5 Isotretinoin Days 1–21 *100 mg/m
2 80 60 60
Thalidomide Daily *400 mg 400 400 200
6 Thalidomide Daily *400 mg 400 400 200
Celecoxib Given twice daily *800 mg 800 800 400
7 Isotretinoin Days 1–21 *100 mg/m
2 80 60 60
Celecoxib Given twice daily *800 mg 400 200 200
8 Isotretinoin Days 1–21 100 mg/m
2 *80 60 60
Thalidomide Daily *400 mg 400 400 200
Celecoxib Given twice daily *800 mg 400 200 200
*Final phase II dose.
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phosphatase, lactate dehydrogenase, serum glutamic
pyruvic transaminase, serum glutamic oxaloacetic trans-
aminase, and anticonvulsant levels (where appropriate)
were performed before randomization and before each
cycle of therapy. For patients receiving celecoxib, stools
were evaluated for occult blood and creatinine clearance
beforetreatmentandevery2cyclesthereafter.Forpatients
receiving isotretinoin, serum cholesterol and triglycerides
were assessed before treatment and every 2 cycles there-
after.Amongpatientsreceivingthalidomide,prothrombin
timeandInternationalNormalizedRatioweredetermined
before each cycle of treatment.
Toxicity was assessed at the end of the ﬁrst 4 weeks of
adjuvant treatment (deﬁned as cycle 1) and graded
according to the National Cancer Institute’s Common
Toxicity Criteria (CTC) version 3.0. If dose-limiting
adverse events were reported, the dose of the drug was
reduced by 1 dose level (to level 21) as indicated in
Table 1. Dose-limiting adverse events were deﬁned as
any CTC grade 3 or higher nonhematologic toxicity,
any CTC grade 3 hematologic toxicity that did not
resolve to less than grade 2 within 2 weeks, or any
CTC grade 4 hematologic toxicity. If subsequent dose-
limiting adverse events occurred at the reduced dose,
the dose was reduced to level 22 and ﬁnally to level
23. Intolerance to the drugs at level 23 resulted in the
patient coming off the study.
Evaluation of treatment effect was performed after
every 2 cycles and determined by serial brain-imaging
studies, most commonly with GD-DPTA MRI.
Radiologic response and progression were evaluated
using Macdonald criteria.
19
Statistical Analysis
Median survival was estimated using the Kaplan–Meier
method from time of registration in the trial to time of
progression, death, or date of last follow-up. Statistical
analysis was done using the SPSS statistical software
(version 17.0, 2009, SPSS, Inc.). Toxicity and survival
analyses included all patients enrolled in the study.
Results
Patients
A total of 54 patients were accrued to the 5 treatment
arms included in the phase I portion of the study (arms
1, 5, 6, 7, and 8). Median age was 52 years, median
KPS was 90, and median follow-up was 15.3 months.
Baseline patient characteristics are shown in Table 2.
Of the 54 patients accrued, 12 (22%) patients did not
receive any adjuvant treatment after chemoradiation, pri-
marily because of evidence of disease progression (n ¼
10) on the GD-DPTA MRI scan performed 4 weeks after
XRT. In addition, 1 patient had a severe fungal infection
and 1 patient withdrew consent. The remaining 42
patients were randomized to adjuvant therapy with temo-
zolomide monotherapy (arm 1; n ¼ 19) or to arm 5 (n ¼
7), arm 6 (n ¼ 4), arm 7 (n ¼ 3), or arm 8 (n ¼ 9). Ten
patients discontinued adjuvant treatment because of tox-
icity, including unresolved neutropenia (n ¼ 7), tremors
(n ¼ 1), fatigue (n ¼ 1), and rash (n ¼ 1), and 22 patients
discontinued treatment before completing all 12 cycles
because of disease progression. Dose adjustments were
required for 1 patient each in treatment arms 5 and 8
becauseofdose-limitingtoxicity.Theﬁnaldosingschedule
for each arm is indicated in Table 1 by the asterisk (*).
Safety
The most commonly reported adverse events were related
to hematologic toxicity. Lymphopenia, as expected, was
common and occurred in 63% of patients, with an
average duration of 26 days. Neutropenia was noted in
25% of patients, with an average duration of 8 days,
although no signiﬁcant infectious complications were
seen during the adjuvant chemotherapy phase of the
study. Additionally, thrombocytopenia occurred in 5
(9%) patients. Fatigue was the most frequently reported
nonhematologic adverse event, and 10 (18%) patients
reported CTC grade 3 fatigue. Seven patients developed
thrombotic complications, 4 of whom were randomized
to treatment regimens that contained thalidomide.
Dose-limiting toxicity occurred in 2 patients during the
ﬁrst cycle of adjuvant treatment. One patient in arm 5
receivingtemozolomide plusthalidomideand isotretinoin
experiencedCTCgrade3fatigueandrash,and1patientin
arm 8 receiving all 4 drugs experienced grade 4 neutrope-
nia.Grade3/4adverseeventsbytreatmentarmareshown
in Table 3.
Survival Results
All enrolled patients were included in the survival analy-
sis, including those who did not receive the adjuvant
component of treatment because of progression after
chemoradiation. As shown in the Kaplan–Meier plot
in Fig. 2, the overall median survival was 20 months
(95% conﬁdence interval 16.5–23.5 months) and the
2-year survival rate was 40%. The overall median
follow-up at the time of this analysis was over 5 years.
Ten patients remain alive ranging in length from 4.8 to
6.9 years from entry onto the study.
Table 2. Baseline patient and disease characteristics (n ¼ 54)
Characteristic
Median age (range), years 52 (18–76)
Gender, n (%)
Male 32 (59)
Female 22 (44)
Karnofsky performance status, n (%)
100 16 (30)
90 20 (37)
80 14 (26)
70 3 (5)
60 1 (2)
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Treatment of glioblastoma remains a challenge.
Although combined chemoradiation with temozolomide
plus XRT followed by adjuvant temozolomide signiﬁ-
cantly improves survival compared with XRT alone,
6
the majority of patients will eventually fail this treat-
ment, and survival at 2 years remains disappointingly
low. A growing bodyof evidence suggeststhat increasing
the dose intensity of temozolomide may improve time to
progression and eventually survival by modulating
resistance mechanisms in the tumor.
20 Preliminary data
from the subgroup analysis of patients enrolled in the
EORTC/NCIC trial support the concept that MGMT
plays a signiﬁcant role in resistance to temozolomide.
7
The present study evaluated the tolerability of the
7/14-day dose-dense temozolomide schedule in the adju-
vant setting following chemoradiation. As previously
described by Wick et al.
9 in patients with recurrent glio-
blastoma, we demonstrated that this regimen is feasible
and generally well tolerated. As expected, the most
important toxicity was hematologic. As previously
described,
21 lymphopenia developed in more than half
of the patients. However, no signiﬁcant risk of infections
was observed, despite the fact that patients in the present
study did not routinely receive prophylaxis for
opportunistic infections. This stands in contrast to other
studies with dose-dense temozolomide schedules that
have reported a higher incidence of opportunistic infec-
tions.
21,22 The combination of cytostatic agents with
dose-dense temozolomide resulted in additional toxicity.
Of particular importance, these combination regimens
may moderately increase the incidence of hematologic
toxicity, particularly neutropenia, although there were
no apparent infectious complications. The rate of myelo-
toxicity mandating treatment cessation in this study was
16%, which is higher than the toxicity-related treatment
discontinuation rate (9%) reported by Stupp et al. with
the conventional single-agent temozolomide at 150–
200 mg/m
2 administered on days 1–5 of a 28-day
cycle.
6 One interesting observation is the apparent
increase in thrombotic events in patients receiving thali-
domide. A risk of thrombotic events associated with anti-
angiogenic agents, including thalidomide, bevacizumab,
and sunitinib, has been previously described but the
underlying mechanisms remain poorly understood.
23
AlthoughthephaseIportionofthisstudywasprimar-
ily designed to determine the safety of dose-dense temo-
zolomideincombinationwithmultiplecytostaticagents,
efﬁcacy data were also collected. Although patients with
disease progression aftercompleting concurrent chemor-
adiation were not continued on this study, these patients
were included in the efﬁcacy analysis. Therefore, these
data closely emulate most published clinical trials in
patients with newly diagnosed glioblastoma. With a
median follow-up of over 5 years, the observed median
survival of 20 months and a 2-year survival rate of
40% compares very favorably with the 14.6-month
median survival and 26% 2-year survival rate observed
in the chemoradiation arm in the EORTC/NCIC trial
reported by Stupp et al.
6 Although these efﬁcacy results
look promising, this component of the trial was not
powered to truly evaluate efﬁcacy.
In conclusion, the phase I portion of this study
demonstrated that a dose-dense schedule of temozolo-
mide is tolerable in the adjuvant setting, and it is feasible
to combine it concurrently with as many as 3 cytostatic
agents. Preliminary efﬁcacy data suggest that there may
be a potential beneﬁt to this approach, although the
number of patients receiving any particular combination
was small. Successful completion of this phase I study
has permitted launching of the full 8-arm phase II
Table 3. Grade 3/4 adverse events by treatment arm
Adverse event Patients, grade 3/4
Chemoradiation
only
Arm 1
(n 5 19)
Arm 5
(n 5 7)
Arm 6
(n 5 4)
Arm 7
(n 5 3)
Arm 8
(n 5 9)
Total (adjuvant)
(n 5 42)
Lymphopenia 2/01 4 /01 /41 /20 /17 /12 3 /8
Leukopenia 0/05 /04 /01 /01 /15 /01 6 /1
Thrombocytopenia 1/01 /01 /00 /00 /11 /04 /1
Neutropenia 0/03 /03 /11 /01 /11 /39 /4
Fatigue 3/01 /02 /02 /00 /02 /01 0 /0
Discontinuations because of
adverse events
1 4 3 2 0 10 (24)
Fig. 2. Kaplan–Meier estimate of survival for all enrolled patients
(n ¼ 54).
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demonstrate the utility and efﬁciency of the factorial
design, which will permit rapid testing of multiple com-
bination regimens in future trials. This is important in
light of the rapid development of numerous cytostatic
agents with potential activity in gliomas, particularly
those designated as signal transduction modulators,
and could be further enhanced by incorporation of
tumor-based correlative studies.
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